Treatment of prostate cancer according to life expectancy, comorbidity and clinical practice guidelines
DOI:
https://doi.org/10.23938/ASSN.0320Keywords:
Prostate neoplasm. Practice Clinic Guidelines. Adverse effects. Treatment. Charlson index.Abstract
Background. To describe the treatment of prostate cancer patients according to life expectancy, risk and comorbidity, to examine the degree to which Clinical Practice Guidelines (CPG) are followed, and to register secondary effects after one year.
Methods. Retrospective study of patients diagnosed with prostate cancer in a hospital in 2011. Socio-demographic variables, as well as comorbidity (Charlson index), tumor characteristics, treatments and secondary effects were collected. A bivariate analysis was performed using the Chi square test.
Results. One hundred and fourteen patients were identified. Life expectancy was higher than 10 years in 92.1%; 50% had low comorbidity, 36% medium and 14% high. Surgery was performed in 56.2%, more often in patients with intermediate-risk and low comorbidity; radiotherapy in 13.2%, more often in patients with high-risk and low comorbidity; hormonal therapy in 21.9%, more often in patients with medium comorbidity, and deferred treatment in 12.3%. CPG recommendations were not followed in 38.6%, especially in high-risk patients, 58.1%. Regarding adverse effects, 70% of patients treated with surgery presented urinary incontinence, and 48.3% erectile dysfunction. On the other hand, 17.15% of patients treated with hormonal therapy presented a cardiovascular disease, and 32.5% worsening of a cardiovascular risk factor.
Conclusions. Treatment of prostate cancer takes into account risk and comorbidity, but there could be improvement in following CPG guidelines, especially in elderly patients. It is advisable to develop preventive strategies to avoid cardiovascular effects in patients with hormonal therapy.
Downloads
References
1. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. [Consultado 25/04/2014]. Disponible en: http://globocan.iarc.fr/.
2. Mortalidad de cáncer en España. [Consultado 25/04/2014]. Disponible en: http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-epidemiologia-ambiental-y-cancer/mortalidad-cancer-en-espana.shtml.
3. NÚÑEZ C, ANGULO J, SÁNCHEZ-CHAPADO M, ALONSO S, PORTILLO JA, VILLAVICENCIO H. Variabilidad de la práctica clínica urológica en cáncer de próstata en España. Actas Urol Esp 2012; 36: 333-339
https://doi.org/10.1016/j.acuro.2012.02.003
4. CHODAK GW, THISTED RA, GERBER GS, JOHANSSON JE, ADOLFSSON J, JONES GW et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 33: 242-248.
https://doi.org/10.1056/NEJM199401273300403
5. ALBERTSEN PC, HANLEY JA, FINE J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-2101.
https://doi.org/10.1001/jama.293.17.2095
6. MENON M, PARULKAR BG, BAKER S. Should we treat localized prostate cancer? An opinion. Urology 1995; 46: 607-616.
https://doi.org/10.1016/S0090-4295(99)80289-1
7. KRAHN MD, BREMNER KE, ASARIA J, ALIBHAI SM, NAM R, TOMLINSON G et al. The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology 2002; 60: 258-263.
https://doi.org/10.1016/S0090-4295(02)01712-0
8. WOLFF JL, STARFIELD B, ANDERSON G. Prevalence, expenditures and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002; 162: 2269-2276.
https://doi.org/10.1001/archinte.162.20.2269
9. GIJSEN R, HOEYMANS N, SCHELLEVIS FG, RUWAARD D, SATARIANO WA, VAN DEN BOS GA. Causes and consequences of comorbidity: A review. J Clin Epidemiol 2001; 54: 661-674.
https://doi.org/10.1016/S0895-4356(00)00363-2
10. DASKIVICH TJ, CHAMIE K, KWAN L, LABO J, PALVOLGYI R, DASH A et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 2011; 117: 2058-2066.
https://doi.org/10.1002/cncr.25751
11. FERRER FORÉS M, RUEDA MARTÍNEZ DE SANTOS JR, LATORRE GARCÍA K, GUTIÉRREZ IBARLUZEA I; Grupo Multicéntrico Español de Cáncer de Próstata Localizado. Efectividad a largo plazo de la prostatectomía radical, la braquiterapia y la radioterapia conformacional externa 3D en el cáncer de próstata órgano-confinado. Madrid: Plan de Calidad para el Sistema Nacional de Salud. Ministerio de Sanidad y Consumo. Agència d'Avaluació de Tecnologia i Recerca Mèdiques de Cataluña, 2008. Informes de Evaluación de Tecnologías Sanitarias, AATRM núm. 2006/08.
12. PAGLIARULO V, BRACARDA S, EISENBERGER MA, MOTTET N, SCHRÖDER FH, STERNBERG CN et al. Contemporany role of androgen deprivation therapy for prostate cancer. Eur Urol 2012; 61: 11-25.
https://doi.org/10.1016/j.eururo.2011.08.026
13. HEINDENREICH A, BASTIAN J, BOLLA M, JONIAU S, MASON M.D, MATVEEV V et al. EAU Guidelines on Prostate Cancer. Eur Urol 2011.
14. CHARLSON ME, POMPEI P, ALES KL, MACKENZIE CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
https://doi.org/10.1016/0021-9681(87)90171-8
15. PALOMO L, RUBIO C, GÉRVAS J. The comorbidity in primary care. Gac Sanit 2006; 20: 182-191.
https://doi.org/10.1157/13086042
16. NGUYEN-NIELSEN M, FRØSLEV T, FRIIS S, BORRE M, HARVING N, SØGAARD M. Completeness of prostate cancer staging in the Danish Cancer Registry, 2004-2009. Clin Epidemiol 2012; 4: 17-23.
https://doi.org/10.2147/CLEP.S32004
17. D'AMICO AV, COTE K, LOFFREDO M, RENSHAW AA, SCHULTZ D. Determinants of prostate cancerspecific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002; 20: 4567-4573.
https://doi.org/10.1200/JCO.2002.03.061
18. D'AMICO AV, WHITTINGTON R, MALKOWICZ SB, SCHULTZ D, BLANK K, BRODERICK GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or intersticial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
https://doi.org/10.1001/jama.280.11.969
19. DE GROOT V, BECKERMAN H, LANKHORST GJ, BOUTER LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003; 56: 221-229.
https://doi.org/10.1016/S0895-4356(02)00585-1
20. MARUSIĆ G, VOJINOV S, LEVAKOV I. Treatment of locally advanced prostatic cancer. Med Pregl 2010; 63: 689-695.
https://doi.org/10.2298/MPNS1010689M
21. RINCÓN MAYANS A, ZUDAIRE B, BRUGAROLAS J, RIOJA J, ZUDAIRE J, ROSELL D et al. Cáncer de prostata localizado de alto riesgo tratado mediante prostatectomía radical. Pronóstico y estudio de variables influyentes. An Sist Sanit Navar 2012; 35: 9-18
https://doi.org/10.4321/S1137-66272012000100002
22. WOLF JS JR, HUBBARD H, FARADAY MM, FORREST JB. Clinical practice guidelines to inform evidence-based clinical practice. World J Urol 2011; 29: 303-309.
https://doi.org/10.1007/s00345-011-0656-5
23. SAYLOR PJ, SMITH MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2013; 189: 34-42.
https://doi.org/10.1016/j.juro.2012.11.017
24. AKBAL C, TINAY I, SIMŞEK F, TURKERI LN. Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment. Int Urol Nephrol 2008; 40: 355-363.
https://doi.org/10.1007/s11255-007-9247-1
25. SAIGAL CS, GORE JL, KRUPSKI TL, HANLEY J, SCHONLAU M, LITWIN MS; Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493-1500.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
